CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Up 58.7% in May

Posted by Brenda Bartman on Jun 16th, 2026

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP – Get Free Report) saw a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 48,551 shares, an increase of 58.7% from the May 14th total of 30,584 shares. Based on an average trading volume of 128,880 shares, the days-to-cover ratio is presently 0.4 days. Approximately 3.3% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.00.

Get Our Latest Stock Report on CNSP

Insiders Place Their Bets

In other news, Director Faith L. Charles purchased 7,100 shares of the company’s stock in a transaction on Monday, May 18th. The shares were acquired at an average price of $4.79 per share, for a total transaction of $34,009.00. Following the purchase, the director owned 7,100 shares in the company, valued at $34,009. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.01% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Ikarian Capital LLC acquired a new position in CNS Pharmaceuticals in the fourth quarter valued at approximately $241,000. Boothbay Fund Management LLC purchased a new position in shares of CNS Pharmaceuticals during the 4th quarter valued at approximately $71,000. Finally, Armistice Capital LLC acquired a new position in shares of CNS Pharmaceuticals in the 2nd quarter valued at $335,000. 14.02% of the stock is currently owned by hedge funds and other institutional investors.

CNS Pharmaceuticals Stock Performance

NASDAQ CNSP traded down $0.06 on Tuesday, reaching $4.68. 11,856 shares of the company’s stock traded hands, compared to its average volume of 802,977. CNS Pharmaceuticals has a fifty-two week low of $1.90 and a fifty-two week high of $12.36. The firm has a market cap of $6.84 million, a price-to-earnings ratio of -0.16 and a beta of 3.05. The stock has a 50 day moving average price of $4.19 and a 200-day moving average price of $4.62.

CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($7.30) earnings per share for the quarter, topping the consensus estimate of ($8.82) by $1.52.

About CNS Pharmaceuticals

(Get Free Report)

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.